These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2440559)

  • 1. Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma.
    Carr BI; Rahbar S; Doroshow JH; Blayney D; Goldberg D; Leong L; Asmeron Y
    Cancer Res; 1987 Aug; 47(15):4199-201. PubMed ID: 2440559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation and globin gene expression in patients treated with 5-azacytidine.
    Ley TJ; Anagnou NP; Noguchi CT; Schechter AN; DeSimone J; Heller P; Nienhuis AW
    Prog Clin Biol Res; 1983; 134():457-74. PubMed ID: 6198660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms.
    Yang YM; Pace B
    Pediatr Pathol Mol Med; 2001; 20(1):87-106. PubMed ID: 12673846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
    Curt GA; Kelley JA; Fine RL; Huguenin PN; Roth JS; Batist G; Jenkins J; Collins JM
    Cancer Res; 1985 Jul; 45(7):3359-63. PubMed ID: 2408749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease.
    Dover GJ; Charache SH; Boyer SH; Talbot CC; Smith KD
    Prog Clin Biol Res; 1983; 134():475-88. PubMed ID: 6198661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of 5,6-dihydro-5-azacytidine in extensive, untreated non-small cell lung cancer.
    Holoye PY; Dhingra HM; Umsawasdi T; Murphy WK; Carr DT; Lee JS
    Cancer Treat Rep; 1987 Sep; 71(9):859-60. PubMed ID: 2441864
    [No Abstract]   [Full Text] [Related]  

  • 8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
    Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Pishchik V; Figg WD; Murgo AJ; Steinberg SM
    Clin Cancer Res; 2006 Oct; 12(19):5777-85. PubMed ID: 17020984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
    Fathallah H; Sutton M; Atweh GF
    Ann N Y Acad Sci; 2005; 1054():228-37. PubMed ID: 16339670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
    Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fetal hemoglobin production in adult baboons by 5-azacytidine or by phenylhydrazine-induced hemolysis is associated with hypomethylation of globin gene DNA.
    DeSimone J; Heller P; Schimenti JC; Duncan CH
    Prog Clin Biol Res; 1983; 134():489-500. PubMed ID: 6198662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of hemoglobin F synthesis in patients with beta thalassemia.
    Ley TJ; Nienhuis AW
    Annu Rev Med; 1985; 36():485-98. PubMed ID: 2581500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
    Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter sequence differences may determine maximal hemoglobin F levels in 5-azacytidine treated baboons.
    Lavelle DE; DeSimone J
    Prog Clin Biol Res; 1989; 316A():261-8. PubMed ID: 2480610
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
    Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of 5-azacytidine in solid tumors.
    Quagliana JM; O'Bryan RM; Baker L; Gottlieb J; Morrison FS; Eyre HJ; Tucker WG; Costanzi J
    Cancer Treat Rep; 1977; 61(1):51-4. PubMed ID: 67893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer.
    Natale RB
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):2-6. PubMed ID: 8941402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.